Skip to main content

Day: August 18, 2020

Mydecine™ Launches World’s First Natural-Sourced cGMP Psilocybin for Global Research, Sales, and Distribution Enterprise

DENVER, Aug. 18, 2020 (GLOBE NEWSWIRE) — Mydecine Innovations Group, Inc., (CSE:MYCO) (OTC:MYCOF) (FSE:0NFA) (“Mydecine™” or the “Company”) is pleased to announce it is the first organization to exercise its cGMP(₁) capabilities under a special license to legally produce, transfer, sell, and export pharmaceutical-grade psilocybin, naturally derived from whole-mushroom extraction.Under the coverage of a Health Canada Schedule 1 Controlled Drugs and Substances Dealer’s Licence, Mydecine™ has the full range of capabilities to extract fungi’s natural psychedelic compounds, such as psilocybin and psilocin from certain species of fruiting body mushrooms all the way through to distribution. Mydecine™ also has the ability to conduct the most advanced techniques to produce purified pharmaceutical-grade extract,...

Continue reading

Patriot One Announces CEO Leadership Transition

TORONTO, Aug. 18, 2020 (GLOBE NEWSWIRE) — Patriot One Technologies Inc. (TSX: PAT) (OTCQX: PTOTF) (FRANKFURT: 0PL) (“Patriot One” or the “Company)  announces that Martin Cronin, the Company’s Chief Executive Officer (CEO) and one of its early founding members, will be stepping down from his position as CEO.  Having overseen the successful rollout of the PATSCAN™ Multi-Sensor Threat Detection Platform and the commencement of initial sales of the product, Mr. Cronin will remain CEO and a Board Member until his replacement has been found, after which he will remain on the Board in an advisory role spearheading new technologies and partnership opportunities.  The Company has initiated its search for a new CEO with sales and business development experience as the Company moves from the start-up phase to full scale operations.“We’re...

Continue reading

Aemetis Regains Compliance with NASDAQ Listing Requirements

CUPERTINO, CA, Aug. 18, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Aemetis, Inc. (NASDAQ: AMTX) announced it received a letter from The NASDAQ Stock Market (“NASDAQ”) on August 11, 2020, which contained a NASDAQ compliance determination that the Company has regained compliance with NASDAQ Listing Rule 5450(b)(2)(C), which requires that listed securities maintain a minimum market value of publicly held shares of the Company’s common stock equal to or in excess of the $15,000,000 minimum.  On August 12, 2020, Aemetis received a letter from NASDAQ confirming compliance with NASDAQ Listing Rule 5450(a)(1), which requires that listed securities maintain a closing bid price equal to or in excess of $1.00 per share.The NASDAQ letters noted that the Company’s common stock has maintained a closing bid price of at least $1.00 per share...

Continue reading

Indberetning af ledende medarbejderes og disses nærtståendes transaktioner med aktier i Hvidbjerg Bank A/S

Banken har på vegne af et bestyrelsesmedlem skulle foretage køb af Hvidbjerg Bank aktier. Ved en fejl er der indtastet stk. i stedet for beløb, hvilket har bevirket, at pågældende har fået 7.100 stk. aktier til en værdi af 418.421,50 kr. i stedet for som anmodet 223 stk. aktier.For yderligere detaljer henvises til det vedhæftede skema, hvori transaktioner udført af personer med ledelsesansvar og personer med nær tilknytning til disse skal indberettes og offentliggøres.Kontaktperson for denne meddelelse er bankdirektør Jens Odgaard på tlf. 96955220Vedhæftet filIndberetning af køb – Bilag

Continue reading

GDS Holdings Limited Reports Second Quarter 2020 Results

SHANGHAI, China, Aug. 18, 2020 (GLOBE NEWSWIRE) — GDS Holdings Limited (“GDS Holdings”, “GDS” or the “Company”) (NASDAQ: GDS), a leading developer and operator of high-performance data centers in China, today announced its unaudited financial results for the second quarter ended June 30, 2020.Second Quarter 2020 Financial HighlightsNet revenue increased by 36.2% year-over-year (“Y-o-Y”) to RMB1,342.2 million (US$190.0 million) in the second quarter of 2020 (2Q2019: RMB985.2 million).Service revenue increased by 35.5% Y-o-Y to RMB1,334.5 million (US$188.9 million) in the second quarter of 2020 (2Q2019: RMB985.1 million).Net loss was RMB101.0 million (US$14.3 million) in the second quarter of 2020, compared with a net loss of RMB93.2 million in the second quarter of 2019.   Adjusted EBITDA (non-GAAP) increased by 47.8% Y-o-Y to RMB633.4...

Continue reading

Eat. Energize. And Find Freshii on Flipp

TORONTO, Aug. 18, 2020 (GLOBE NEWSWIRE) — Today, Freshii Inc. (TSX: FRII) (“Freshii”), the growing health and wellness brand and Flipp, a leader in retail technology, announced their partnership to offer Canadians value and savings content on the Flipp app. From now until September 10, Canadians can find great deals from Freshii on bowls for two, meals for three and plenty more!“We want to stay true to our commitment to making healthy food affordable and convenient, especially during these times,” said Estefania Bafunno, Director, Marketing at Freshii. “We continue to invest in digital marketing efforts and with Flipp’s target audience so aligned to Freshii’s, it was a natural fit to use this platform to offer value to our customers..”Flipp launched the Restaurant section on the app in 2020, offering Canadians great...

Continue reading

XPO Logistics Named a Top 100 Trucker by Inbound Logistics

GREENWICH, Conn., Aug. 18, 2020 (GLOBE NEWSWIRE) —  XPO Logistics, Inc. (NYSE: XPO), a leading global provider of supply chain solutions, has been named a Top 100 Trucker by Inbound Logistics magazine for the 5th consecutive year. The 2020 Top 100 Truckers were selected from a broad range of transportation providers, including large truckload and less-than-truckload carriers, regional haulers and niche providers, such as last mile.Troy Cooper, president of XPO Logistics, said, “We’re honored that Inbound Logistics has once again recognized the value of our transportation services. We went into these challenging times with strong digital capabilities for freight management on our XPO Connect platform. Our ability to source capacity in atypical market environments is serving our customers well.”To determine the top truckers, Inbound...

Continue reading

GobiMin Announces Second Quarter 2020 Results

MONTREAL, Aug. 18, 2020 (GLOBE NEWSWIRE) — (TSXV: GMN) GobiMin Inc. (“GobiMin” or the “Company”, together with its subsidiaries collectively the “Group”) reports its financial and operating results for the second quarter of 2020.  The unaudited condensed interim financial statements along with quarterly highlights of management’s discussion and analysis have been filed with SEDAR (www.sedar.com) and are also available at the website of the Company (www.gobimin.com). Financial HighlightsNote:(1) As non-IFRS measurements, EBITDA/(LBITDA) (earnings/(loss) before interest income and expense, income taxes, depreciation and amortization), EBITDA/(LBITDA) per share and Cash and cash equivalents per share do not comply with IFRS and, therefore, the amounts presented in the above table may not be comparable to similar data presented by other...

Continue reading

Immatics Announces European Clinical Expansion of its Adoptive Cell Therapy Programs

Tuebingen, Germany and Houston, Texas, Aug. 18, 2020 (GLOBE NEWSWIRE) —First patient has been treated in Germany in Immatics’ ACTengine® IMA202-101 trialGerman regulatory agency, Paul-Ehrlich-Institute (PEI), granted approval to commence another clinical ACTengine® trial in Germany investigating Immatics’ IMA203 product candidateThree clinical trial sites in Germany have started recruiting patients for Immatics’ ACTengine® IMA200 trial seriesTuebingen, Germany and Houston, Texas, August 18, 2020 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting cancer immunotherapies, announced today the treatment of the first patient in the IMA202-101 trial in Europe following the Clinical Trial Application (CTA, the equivalent of an IND approval by...

Continue reading

Immatics weitet klinisches Studienprogramm für adoptive Zelltherapien auf Europa aus

Tübingen, Deutschland und Houston, Texas, Aug. 18, 2020 (GLOBE NEWSWIRE) —Der erste Patient in Deutschland wurde im Rahmen der Immatics‘ ACTengine® IMA202-101 Studie behandeltDie deutsche Zulassungsbehörde, das Paul-Ehrlich-Institut (PEI), hat den Antrag (CTA, Clinical Trial Application) für eine weitere klinische ACTengine®-Studie in Deutschland genehmigt. Die Studie wird Immatics‘ Produktkandidaten IMA203 untersuchenDrei klinische Studienzentren haben in Deutschland mit der Patienten-Rekrutierung für Immatics‘ ACTengine®-IMA200-Studienprogramme begonnen  Tübingen, Deutschland und Houston, Texas, 18. August 2020 – Immatics N.V. (NASDAQ: IMTX, „Immatics“), ein Unternehmen, das sich auf die Entwicklung und Herstellung von T-Zell-Immuntherapien für die Behandlung von Krebs fokussiert, gab heute die Behandlung des ersten Patienten im...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.